Medicine, Faculty of
Non UBC
DSpace
International Journal of Molecular Sciences 22 (2): 824 (2021)
University of British Columbia. Allan McGavin Sports Medicine Clinic
Padilla, Sabino
Sánchez, Mikel
Vaquerizo, Victor
Malanga, Gerard A.
Fiz, Nicolás
Azofra, Juan
Rogers, Christopher J.
Samitier, Gonzalo
Sampson, Steven
Seijas, Roberto
Elorriaga, Ricardo
Taunton, Jack E.
Boehm, Frank
Prado, Roberto
Cugat, Ramón
Anitua, Eduardo
Achilles tendon ruptures are very common tendon ruptures and their incidence is increasing in modern society, resulting in work incapacity and months off sport, which generate a need for accelerated and successful therapeutic repair strategy. Platelet-rich plasma (PRP) is emerging as adjuvant human blood-derived constructs to assist Achilles tendon rupture treatment. However, myriad PRP preparation methods in conjunction with poor standardization in the modalities of their applications impinge on the consistent effectiveness of clinical and structural outcomes regarding their therapeutic efficacy. The purpose of this review is to provide some light on the application of PRP for Achilles tendon ruptures. PRP has many characteristics that make it an attractive treatment. Elements such as the inclusion of leukocytes and erythrocytes within PRP, the absence of activation and activation ex vivo or in vivo, the modality of application, and the adjustment of PRP pH can influence the biology of the applied product and result in misleading therapeutic conclusions. The weakest points in demonstrating their consistent effectiveness are primarily the result of myriad PRP preparation methods and the poor standardization of modalities for their application. Selecting the right biological scaffold and applying it correctly to restitutio ad integrum of ruptured Achilles tendons remains a daunting and complex task.
International Journal of Molecular SciencesReviewPlatelet-Rich Plasma Applications for Achilles Tendon Repair:A Bridge between Biology and SurgerySabino Padilla 1,2,3,* , Mikel Sánchez 4,5 , Victor Vaquerizo 6 , Gerard A. Malanga 7,8,9 , Nicolás Fiz 4,5 ,Juan Azofra 4,5 , Christopher J. Rogers 10, Gonzalo Samitier 11,12,13 , Steven Sampson 14,15 ,Roberto Seijas 11,12,13 , Ricardo Elorriaga 16 , Jack Taunton 17, Frank Boehm 18, Roberto Prado 1,2,3 ,Ramón Cugat 11,12,13 and Eduardo Anitua 1,2,3,*Citation: Padilla, S.; Sánchez, M.;Vaquerizo, V.; Malanga, G.A.; Fiz, N.;Azofra, J.; Rogers, C.J.; Samitier, G.;Sampson, S.; Seijas, R.; et al.Platelet-Rich Plasma Applications forAchilles Tendon Repair: A Bridgebetween Biology and Surgery. Int. J.Mol. Sci. 2021, 22, 824. https://doi.org/10.3390/ijms22020824Received: 23 December 2020Accepted: 10 January 2021Published: 15 January 2021Publisher’s Note: MDPI stays neu-tral with regard to jurisdictional clai-ms in published maps and institutio-nal affiliations.Copyright: © 2021 by the authors. Li-censee MDPI, Basel, Switzerland.This article is an open access articledistributed under the terms and con-ditions of the Creative Commons At-tribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).1 Eduardo Anitua Foundation for Biomedical Research, Jacinto Quincoces, 39, 01007 Vitoria, Spain;roberto.prado@bti-implant.es2 BTI-Biotechnology Institute ImasD, Jacinto Quincoces, 39, 01007 Vitoria, Spain3 University Institute for Regenerative Medicine & Oral Implantology-UIRMI (UPV/EHU-Fundación EduardoAnitua), Jacinto Quincoces, 39, 01007 Vitoria, Spain4 Arthroscopic Surgery Unit, Hospital Vithas Vitoria, Beato Tomás de Zumarraga 10, 01008 Vitoria-Gasteiz,Spain; mikel.sanchez@ucatrauma.com (M.S.); nicolas.fiz@ucatrauma.com (N.F.);juan.azofra@ucatrauma.com (J.A.)5 Advanced Biological Therapy Unit, Hospital Vithas Vitoria, 01008 Vitoria-Gasteiz, Spain6 Department of Orthopaedic Surgery, Príncipe de Asturias University Hospital,28805 Alcalá de Henares, Spain; vaquerizovictor@yahoo.es7 New Jersey Regenerative Institute LLC, Cedar Knolls, NJ 07927, USA; gmalangamd@hotmail.com8 Department of Physical Medicine and Rehabilitation, Rutgers School of Biomedical and Health Sciences,Newark, NJ 07901, USA9 Rutgers University and New Jersey Regenerative Medicine Institute, Cedar Knolls, NJ 07927, USA10 San Diego Orthobiologics Medical Group, Inc., Carlsbad, CA 92011, USA; rogers@sdomg.com11 Instituto Cugat, Plaza Alfonso Comín 5-7, Planta (-1), 08023 Barcelona, Spain;samitier@sportrauma.com (G.S.); seijastraumatologia@gmail.com (R.S.); ramon.cugat@sportrauma.com (R.C.)12 Fundación García Cugat, c/Madrazo 43, 08006 Barcelona, Spain13 Hospital Quirónsalud Barcelona, Plaza Alfonso Comín 5, 08023 Barcelona, Spain14 David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095, USA;drsampson@orthohealing.com15 The Orthohealing Center, 10780 Santa Monica Blvd, Suite 210, Los Angeles, CA 90025, USA16 Servicio de Cirugía Ortopédica y Traumatología, Hospital Universitario de Basurto, Montevideo Etorb, 18,48013 Bilbao, Spain; rielorriaga@gmail.com17 Division of Sports Medicine, Allan McGavin Sports Medicine Centre, University of British Columbia,Chan Gunn Pavilion 2553 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada; jack.taunton@ubc.ca18 NanoApps Medical, Inc., Vancouver, BC V6K 1C8, Canada; frankboehm@nanoappsmedical.com* Correspondence: sabinopadilla@hotmail.com (S.P.); eduardo@fundacioneduardoanitua.org (E.A.);Tel.: +34-945-160-653 (S.P.)Abstract: Achilles tendon ruptures are very common tendon ruptures and their incidence is increas-ing in modern society, resulting in work incapacity and months off sport, which generate a needfor accelerated and successful therapeutic repair strategy. Platelet-rich plasma (PRP) is emerging asadjuvant human blood-derived constructs to assist Achilles tendon rupture treatment. However,myriad PRP preparation methods in conjunction with poor standardization in the modalities of theirapplications impinge on the consistent effectiveness of clinical and structural outcomes regardingtheir therapeutic efficacy. The purpose of this review is to provide some light on the application ofPRP for Achilles tendon ruptures. PRP has many characteristics that make it an attractive treatment.Elements such as the inclusion of leukocytes and erythrocytes within PRP, the absence of activa-tion and activation ex vivo or in vivo, the modality of application, and the adjustment of PRP pHcan influence the biology of the applied product and result in misleading therapeutic conclusions.The weakest points in demonstrating their consistent effectiveness are primarily the result of myriadPRP preparation methods and the poor standardization of modalities for their application. Selectingthe right biological scaffold and applying it correctly to restitutio ad integrum of ruptured Achillestendons remains a daunting and complex task.Int. J. Mol. Sci. 2021, 22, 824. https://doi.org/10.3390/ijms22020824 https://www.mdpi.com/journal/ijmsInt. J. Mol. Sci. 2021, 22, 824 2 of 17Keywords: Achilles; platelet-rich plasma; PRGF; tendon1. IntroductionAchilles tendon rupture is a common tendon rupture and its incidence is increasing inmodern society due to an aging population, the increasing prevalence of obesity, and ex-panded participation in sports [1]. Affecting the working population and recreationaland professional athletes, Achilles tendon ruptures result in work incapacity and manymonths off sport, creating a significant requirement for accelerated and successful repair,while minimizing fibrosis and functional limitations [1–3]. Achilles tendinopathy is apainful and dysfunctional condition encompassing pathologies ranging from tendinosisor tendinitis to partial and full-thickness tears, where evidence is mounting that points toimmunocompetent cells and activated stromal fibroblasts as the drivers of a non-resolvedinflammatory condition [4–7]. Platelet-rich plasma (PRP) is emerging as an enhancer ofthe natural tendon healing process in the conservative and surgical treatment of Achillestendon ruptures [2,3,8–10]. However, a lingering controversy exists as to whether theseautologous blood-derived products are efficacious and facilitate expedited Achilles tendonrepair [11–15]. The weakest points in demonstrating their consistent effectiveness areprimarily the result of myriad PRP preparation methods and the poor standardization ofmodalities for their application. These elements somehow hamper advancement and leadto contradictory conclusions regarding their therapeutic efficacy [12,14,16].This narrative review is intended to shed some light on the application of PRP for Achillestendon ruptures. It endeavors to bring a number of pitfalls into focus regarding the variedmethods used in PRP generation and the poor standardization of application modalities.2. Aligning Coagulation and Hemostasis with Therapeutic Needs: PRP ProductsRecent work toward deciphering the roles of blood components and of the biochemi-cal machinery underlying the humoral and cellular arms of intravascular innate immunecascade systems, specifically coagulation and hemostasis as well as blood anticoagulationand deconstruction, have led to procedures that filter out platelets and the coagulationmachinery to yield PRP [17]. These blood-derived products consist of fluid phase plasma,where platelets, white cells, and red cells are suspended in different concentrations, de-pending on the specific centrifugation and fractionation processes carried out [18].2.1. When Fibrin Meets Growth FactorsWhen sodium citrate is used as an anticoagulant, the ex vivo recalcification of the fluidphase with CaCl2 reverts the coagulation cascade, which generates trace amounts of nativethrombin that simultaneously induces the activation of platelets and their degranulationand the polymerization of plasma fibrinogen into a progressively functionalized insolublefibrin matrix [17,19]. The newly functionalized three-dimensional fibrin nanoscaffold willbind in a non-diffusible manner and trap several platelet- and plasma-derived growthfactors (GFs), chemokines, cytokines, and other biomolecules (TGFβ1 and β2, VEGF, PDGF,FGF, EGF, CTGF, SDF-1α HGF, IGF1, FXII, IL-8, and C3, among others) through the heparinsulfate proteoglycan domains of adhesive proteins, including fibrinogen, fibronectin (Fn),vitronectin (Vn), and TSP-1 [20–23]. Nevertheless, several GFs, in a diffusible mode,will directly connect with their cognate cell surface receptors (Figure 1A) to induce animmediate effect [22].Int. J. Mol. Sci. 2021, 22, 824 3 of 17Int. J. Mol. Sci. 2021, 22, x FOR PEER REVIEW 3 of 18 Figure 1. An autologous liquid-to-gel dynamic scaffold as a carrier of biological mediators in tissue repair. When liquid plasma rich in growth factors (GFs) is applied directly into tissue, the newly formed three-dimensional matrix clot traps many of the released growth factors and cytokines from platelet degranulation and from plasma by binding them to the heparin sulfate proteoglycan do-mains of fibrin matrix components in a non-diffusible mode (yuxtacrine or matricrine) (A). How-ever, some GFs in a diffusion mode (autocrine and paracrine) will directly reach their cognate cell-surface receptor (D), thereby inducing an immediate cell-biosynthetic and cell-behavior modifica-tion (C). The ensuing progressive biodegradation of a fibrin clot is mediated by the serine protease plasmin, which is yielded through both the activation of plasminogen by a tissue plasminogen acti-vator [24] and the immune and mesenchymal cells that migrate into the clot, thereby matching the speed of the ingrowing repair tissue [17,21,22,25,26] (B). GFs act as extracellular ligands by binding to transmembrane receptors arrayed on the surface of target cells, thereby activating intracellular signal transduction pathways that convey the signal to the nucleus to eventually induce a wide range of cell specifications during inflammation and the repair process including cell survival, pro-liferation, migration, differentiation, and maturation and changes in protein synthesis and metabo-lism (C). These effects include the synthesis and secretion of GFs and cytokines, which interact with their receptors in a diffusible manner (autocrine and paracrine pathways); the synthesis of extracel-lular matrix (ECM) components such as collagens, decorin, hyaluronic acid, and glycosaminogly-cans; and cell survival, proliferation, differentiation, and migration (C) [17]. Only by understanding the unbreakable link between GFs and fibrin matrix will we grasp the in situ biological function of PRP and the additional pivotal fact that it is not necessary to combine this product with other deliv-ery systems to slowdown the release of GFs. In PRP, the architectural keystone is the fibrin matrix, as fibrin transiently binds sev-eral GFs, transports GFs to the vicinity of cells, and facilitates their tissue penetration, . l li i l i f l s rri r f i l ic l e iators i tiss erepair. hen liquid plas a rich in gro th factors ( Fs) is applied directly into tissue, the ne lyformed three-dimensional matrix clot traps many of the released growth factors and cytokines fromplatelet degranulation and from plasma by binding them to the heparin sulfate proteoglycan domainsof fibrin matrix components in a non-diffusible mode (yuxtacrine or matricrine) (A). However,some GFs in a diffusion mode (autocrine and paracrine) will directly reach their cognate cell-surfacereceptor (D), thereby inducing an immediate cell-biosynthetic and cell-behavior modification (C).The ensuing progressive biodegradation of a fibrin clot is mediated by the serine rotease plasmin,which is yiel ed through both the activation of p asminogen by a tissue plasminogen activator [24]and the immune and m senchymal cells that migrate into the clot, thereby matching the speedof the ingrowing repair tissue [17,21,22,25,26] (B). GFs act as extracellular ligands by binding totransmembrane receptors arrayed on the surface of target cells, thereby activating intracellular signaltransduction pathways that convey the signal to the nucleus to eventually induce a wide range ofcell specifications during inflammation and the repair process including cell survival, proliferation,migration, differentiation, and maturation and changes in protein synthesis and metabolism (C).These effects include the synthesis and secretion of GFs and cytokines, which interact with theirreceptors in a diffusible manner (autocrine and paracrine pathways); the synthesis of extracellularmatrix (ECM) compon nts such as collage s, decorin, hyaluronic acid, and glyc saminoglycans;and cell survival, proliferation, differentiation, and migration (C) [17]. Only by understanding theunbreakable link between GFs and fibrin matrix will we grasp the in situ biological function of PRPand the additional pivotal fact that it is not necessary to combine this product with other deliverysystems to slowdown the release of GFs.Int. J. Mol. Sci. 2021, 22, 824 4 of 17In PRP, the architectural keystone is the fibrin matrix, as fibrin transiently binds severalGFs, transports GFs to the vicinity of cells, and facilitates their tissue penetration, spatiallocalization, and in situ delivery (Figure 2) [17,21,27]. Moreover, fibrin circumvents theshort GF half-life, and not only protects GFs from proteolysis, but also serves as a sink formorphogens and dampens the surge of GFs initially released by platelets (in conjunctionwith cytokines from leukocytes and the heme iron from erythrocytes, if present), therebyavoiding the bolus effect (Figure 2) [20,22,23,25,28]. Once an autologous fibrin scaffoldhas been applied, the breakdown of the matrix by tissue fibrinolysis (Figure 1B) releasesGFs both immediately and in a gradual and delayed manner. Therefore, PRP operates as abiomimetic biphasic GF delivery systems, while modulating the spatiotemporal chemo-tactic gradients of the GFs required to induce cell–cell survival, migration, proliferation,differentiation, maturation, and correct orientation in nascent tissues (Figure 1B) [20,27].The GFs released by platelets (among other tissue-resident cells of damaged areas) arebiochemical signaling agents that operate on specifically limited length and time scales inautocrine and paracrine modes (Figure 1D). They diffuse over distances of less than severaltens of micrometers; thus their signal intensity decays more than linearly with the distancefrom the source, roughly 1/r2; in 3D, it is even more rapid [29].Int. J. Mol. Sci. 2021, 22, x FOR PEER REVIEW 4 of 18 spatial localization, and in situ delivery (Figure 2) [17,21,27]. Moreover, fibrin circumvents the short GF half-life, and not only protects GFs from proteolysis, but also serves as a sink for morphogens and dampens the surge of GFs initially released by platelets (in conjunc-tion with cytokines from leukocytes and the heme iron from erythrocytes, if present), thereby avoiding th bolus effect (Figure ) [ 0, 2,23,25,28]. Once an autologous fibrin scaffold h s be n applied, the breakdown of the matrix by tissue fibrinolysis (Figure 1B) releases GFs both immediately and in a gradual an delay d manner. Theref r , PRP op-erates as a biomimetic biphasic GF delivery systems, while modulating the spatiotemporal chemotactic gradients of the GFs required to induce ce l–cell survival, migration, prolifer-ation, differe tiation, matur tion, and c rec orientation in na cent tissues (Figure 1B) [20,27]. Th GFs released by platelets (among other tissue-resid nt cells of damaged areas) are biochemical sig aling agents hat operate on spe ifica ly limited length and time scales in autocrine and paracrine modes (Figure 1D). They diffuse over di tance of le s than s veral tens of micrometers; thus their signal int nsity decays more than linearly with th distanc fr m the source, roughly 1/r2; in 3D, it is even more rapid [29]. Figure 2. Summary of the primary biological and therapeutic features of platelet-rich plasma (PRP). PRP has emerged as an adjuvant human blood-derived constructs to assist tissue engineering and cell therapies in regenerative medicine. Fig-ure adapted from [17] with permission. 2.2. Tendon Tissue Effects of PRP: Multi-Directional Role of Growth Factors PRP is a biodegradable autologous multi-growth factor scaffold product whose bio-logical effect primarily relies on tissue-resident cells as the pivotal target of GFs conveyed by the fibrin liquid-to-gel dynamic scaffold. Ample evidence based on in vitro, in vivo, and clinical trials indicates that GFs, which are present within PRP and PRP products themselves, exert multi-directional biological effects on the mechanisms that govern ten-don tissue repair, including (but not limited to) the following effects: angiogenic [30,31]; antiapoptotic, tenogenic, and proliferative [32–34]; chemotactic, trophic, and biosynthetic [9,30–36]; immunomodulatory and anti-inflammatory [34]; antifibrotic [3,30,31], antialgic [37,38]; and biomechanical [16,39,40]. If we focus on the effect of PRP on the extracellular matrix of rotator cuff tendons, Cross et al. [35] showed, in an elegant study, that leukocyte-free PRP stimulated normal collagen matrix synthesis (the ratio of COL1A1:COL3A1 gene Fig re 2. Su ary of the pri ary biological and therapeutic features of platelet-rich plasma (PRP). PRP has emerged as andjuvant human blood-derived constructs to assist tissue engi eering and cell therapies in regenerative medicine. Figureadapted from [17] with permission.2.2. Tendon Tissue Effects of PRP: ulti- irectional Role of ro th FactorsP P is a biodegradable autologous multi-growth factor scaffold product whose biologi-cal effect primarily relies on tissue-resident cells as the pivotal target of GFs conveyed by thefibrin liquid-to-gel dynamic scaffold. Ample evidence based on in vitr , in vivo, and clini-cal trials indicates that GFs, which are present within PRP and PRP products themselves,ex rt multi-directional biological effects on the mechanisms that govern tendon tissuerepair, including (but not limited to) he following effects: angiogeni [30,31]; antiapoptotic,tenogenic, and pr liferative [32–34]; chemotactic, trophic, nd biosynthetic [9,30–36]; im-munomodulatory and anti-infl mmatory [34]; antifibrotic [3,30,31], antialgic [37,38]; andbiomechanical [16,39,40]. If we focus on the effect of PRP on the extracellular matrix ofInt. J. Mol. Sci. 2021, 22, 824 5 of 17rotator cuff tendons, Cross et al. [35] showed, in an elegant study, that leukocyte-free PRPstimulated normal collagen matrix synthesis (the ratio of COL1A1:COL3A1 gene expres-sion) and decreased the cytokines associated with matrix degradation and inflammation,such as Matrix Metalloproteinases (MMP-9 and MMP-13) and IL-1β. These results werealso confirmed by Yan et al. [36], demonstrating increased gene expression of Collagen 1in PRP-treated Achilles tendons and decreased expression of catabolic proteins such asMMP-1 and MMP-3.In the context of tissue development, regeneration, and repair processes, GFs behave ina combinatorial, synergistic, and multi-directional manner [41], which has inspired regener-ative human-engineered approaches [21,22,41]. Accordingly, many successful strategies fortherapeutic tissue regeneration and repair integrate a combination of several recombinantGFs that are frequently embedded in a fibrin scaffold [21,27], although in higher dosesthan the equivalent native growth factors present within autologous fibrin scaffolds [17].Moreover, GFs within PRP fibrin matrices circumvent some of the drawbacks imposed byrecombinant GFs, including their short half-life and bioavailability, high systemic toxicity,bolus effect, rapid cellular internalization rate, the limited spatial and time scales withinwhich they operate, and the requirement of high therapeutic doses [22,28].2.3. Practical Considerations in the Application of PRP for Achilles Tendon RupturesOur recommended conservative treatment of Achilles tendon ruptures (Figure 3A–C)usually begins with a dynamic ultrasound study, which should assess and verify that bothends of the rupture will approach each other during plantar flexion (evaluating their mobil-ity), meaning that both extremes might heal effectively without excessive elongation [42].Once the treatment strategy has been confirmed and is under ultrasound control, and withthe foot plantar flexed, 6-8 mL of a liquid PRGF formulation is percutaneously infiltratedinto the center of the rupture. In addition, 4 mL of liquid PRGF is infiltrated into each of theproximal and distal ends of the tendon (hyperechogenic ultrasound image of PRGF) [42] torecruit tendon and mesenchymal stem cells, as well as to target the stromal inflammatorymicroenvironment and stromal cell phenotypes, including macrophages and fibroblasts(Figure 3C) [5,43–45]. This infiltration process should be repeated over three consecutiveweeks. The patient’s ankle is immobilized using a Walker-type orthosis in plantar flexion(equinus), which allows for partial and progressive loading. The equinus of the orthosis isprogressively reduced from Week 4 onwards, removing a wedge every week until finalremoval of the orthosis. An ultrasound examination should be performed in Week 4 afterthe final infiltration. If unrepaired rupture regions are detected, the injured zone shouldbe infiltrated again. Ultrasound examinations should be repeated every 4 weeks, togetherwith dynamic testing until complete healing of the rupture is confirmed [42].Int. J. Mol. Sci. 2021, 22, 824 6 of 17Int. J. Mol. Sci. 2021, 2 x FOR PEER REVIEW 6 of 18 Figure 3. Achilles tendon rupture treatment: conservative and surgical treatment assisted by autol-ogous blood or blood-derived products (PRP). (A) Achilles tendon rupture, rupture gap, and hema-toma. (B) Conservative treatment: a single injection of either PRP or autologous blood injected into the gap hematoma. (C) Conservative treatment proposal (in patients with a low functional demand, or for whom surgery is contraindicated). Ultrasound-guided injection of 4 mL of liquid plasma rich in growth factors (PRGF) in close proximity to the apparently healthy tendon tissue at each stump of the tendon and 4–6 mL of liquid PRGF into the gap hematoma; a procedure to be repeated over 2 or 3 consecutive weeks (D–F) Surgical treatment proposal: after the suture is performed with a non-reabsorbable suture material that has been bathed in liquid PRGF (D), 4–6 mL of liquid PRGF is injected in close proximity to the apparently healthy tendon tissue at each stump, as well as into the sutured area (E) within the time window of 10 to 15 min following PRGF activation with CaCl2. This window encompasses the time when the fibrin scaffold is still macroscopically liquid is but undergoing microscopic jellification. Liquid PRGF can extensively permeate through areas that sur-round the injection site and anchor to the collagen and other ECM proteins exposed in damaged tissue margins through the activated platelets conveyed by the fibrin clot, as a 3D fibrin–extracellu-lar matrix-like malleable structure [17], thereby bridging the gap of injured areas. The time window of 1–5 min is the result of the gel point or clotting time, meaning the change from liquid to solid undergone by the matrix when 15–20% of the fibrinogen has been incorporated into the gel by branching points (approximately 4 min 50 s) [46]. After closing the paratenon and prior to closing the overlying skin, the peritendinous regions are also infiltrated with PRGF; finally, the entire af-fected area of the tendon is covered with a fibrin membrane of PRGF (F). As general recommenda-tion, we suggest the use of 10 mL Luer lock-type syringes with 21G needles, since the use of small syringes means that large pressures are exerted on the ECM of the tissue during infiltration, thereby accounting for the focalized disruption of the ECM components (a desirable effect in some treatment protocols aimed at disrupting the neovascularization and neoinnervation present in some chronic tendinopathies) [7,42]. Upon infiltration, the needle should be oriented as closely as possible parallel to, and longitudinal with, the tendon fascicles for an optimal diffusion of PRGF [42]. Figure 3. Achilles tendon rupture treatment: conservative and surgical treatment assisted by autolo-gous blood or blood-derived products (PRP). (A) Achilles tendon rupture, rupture gap, and hematoma.(B) Conservative treatment: a single injection of either PRP r a tol gous blood injected into thegap hematoma. (C) Conservative treatment proposal (in patients with a low functional demand,or for whom surgery is contraindicated). Ultrasound-guided injection of 4 mL of liquid plasma richin growth factors (PRGF) in close proximity to the apparently healthy tendon tissue at each stumpof the tendon and 4–6 mL of liquid PRGF into the gap hematoma; a proce ure to be repeated over2 or 3 consecutive weeks (D–F) Surgical treatment proposal: after the suture is performed with anon-reabsorbable suture material that has been bathed in liquid PRGF (D), 4–6 mL of liquid PRGFis i jected in clos proximity to the apparently healthy tendon tissue t eac st mp, as well as intothe sutured area (E) wit in the time wi dow f 10 to 15 min following PRGF ctivation with CaCl2.This window encompasses the time when the fibrin scaffold is still macroscopically liquid is butundergoing microscopic jellification. Liquid PRGF can extensively permeate through areas that sur-ound the inject on site and anchor to the collagen and other ECM pr eins exposed in damagedtissue margins through the activated platelets conveyed by the fibrin clot, as a 3D fibrin–extracellularmatrix-like malleable structure [17], thereby bridging the gap of injured areas. The time window of1–5 min is the result of the gel point or clotting time, meaning the change from liquid to solid under-one by t e matrix when 15–20% of the fibrinogen has been incorporated into the gel by branchingpoints (approximately 4 min 50 s) [46]. After closing the paratenon and prior to closing the overlyingskin, the peritendinous regions are also infiltrated with PRGF; finally, the entire affected area of thetendon is covered with a fibrin memb a e of PRGF (F). As general recommendation, we suggest theuse of 10 mL Luer lock-type syringes with 21G needles, since the use of small syringes means thatlarge pressures are exerted on the ECM of the tissue during infiltration, thereby accounting for thefocalized disruption of the ECM components (a desirable effect in some treatment protocols aimed atdisrupting the neovascularization and neoinnervation present in some chronic tendinopathies) [7,42].Upon infiltration, the needle should be oriented as closely as possible parallel to, and longitudinalwith, the tendon fascicles for an optimal diffusion of PRGF [42].Int. J. Mol. Sci. 2021, 22, 824 7 of 17For the surgical treatment (recommended for recreational and professional athletes,for whom accelerated functional recovery is essential), the hematoma is evacuated, and thetendon edges are debrided. The tendon is sutured using a non-resorbable material,which has been previously soaked in PRGF, after which PRGF liquid is infiltrated into thesutured area, and the apparently healthy tendon of the proximal and distal stumps (Figure3D,E) similar to the conservative treatment, and finally infiltrated into the peritendinousregions [3,42]. Following the closure of the paratenon and prior to closing the overly-ing skin, the affected area is covered with a PRGF membrane (Figure 3F). Subsequently,an ultrasound examination of the Achilles tendon is performed during the third weekof recovery, the result of which might indicate PRGF infiltration. This proposed surgicaltreatment was initially implemented by Sanchez and colleagues in 2007 [3], who conducteda case–control study on athletes. They reported a faster recovery of motion, quicker re-sumption of sport activities, and a smaller increase in tendon cross-sectional area in contrastto a standard repair procedure after 18 months, a data compatible with a reduced fibroticprocess in the PRGF group [3]. Other groups confirmed the histological and biomechan-ical beneficial effects of this procedure in both animals and humans [8,40]. Achieving ashorter immobilization time enables physiotherapy to be sped up due to the formation ofa more efficient repair tissue. Therefore, for both the conservative and surgical treatmentof Achilles tendon ruptures, early mechanotherapy and physiotherapy are of the utmostimportance, and several studies revealed a synergistic effect between PRGF injections andearly mechanical stimulation [3,47].3. Pitfalls in the Application of PRP for the Repair of Achilles Tendon RupturesThe weakest points in demonstrating the consistent effectiveness of PRP primarilyreside in the myriad PRP preparation methods, in conjunction with poor standardizationin the modalities of their application. These elements somehow hamper advancement andcan lead to misleading conclusions regarding their therapeutic efficacy [12,16–18].3.1. Whole Blood, Platelet-Rich Plasma, or Platelets Only?Whole blood and PRP injections are used to treat Achilles tendon ruptures andtendinopathies with mixed clinical outcomes, which should be of no surprise due toboth the different biological composition of PRP and the varied application modalities(Table 1) [3,6,8,10–14,38,48–54]. As an example of this heterogeneity regarding PRPs, Fitz-patrick et al. [55] conducted a meta-analysis of the effectiveness of PRP in the treatmentof tendinopathies, which included heterogeneous blood-derived products from sevenstudies that used autologous whole blood, 11 studies that used leukocyte-rich PRP (LR-PRP), one study that used autologous conditioned serum, and one study that appliedleukocyte-poor PRP (LP-PRP). PRP products are derived from widely varied methods ofpreparation [18] that generate a plasma fraction whose only common denominator is aplatelet concentration that is superior to peripheral blood.Int. J. Mol. Sci. 2021, 22, 824 8 of 17Table 1. Summary of studies on human Achilles tendon rupture treatment assisted with platelet-rich plasma.Study Features of the Study PRP Characteristics Modality of Application OutcomeSanchez et al. [3]Retrospective case–controlPRGF and surgery n = 6Control n = 6 only surgeryCitrate as anticoagulantActivation with CaCl2Leukocyte- and erythrocyte-freePlatelets 2–3×Injection of 4 mL of PRGF into thesuture and surrounding areas.A PRGF membrane to cover therupture and sutured areaFaster recovery of motion, quicker return to sportingactivities, and a smaller increase in cross-sectional area ontendons treated with PRGF after 18 monthsSanchez et al. [56]Case studyn = 2Surgical repairCitrate as anticoagulantActivation with CaCl2Leukocyte-and erythrocyte-freePlatelets 2–3×Infiltration of 3 mL of PRGF into eachtendon stump.A PRGF membrane covering theaffected areasSuccessful PRGF-assisted management and recovery of majorpost-operative Achilles tendon infection and necrosis afterprimary surgical repair.Schepull et al. [14]Randomized controlled trialPRP n = 16Control n = 14Surgical repairCitrate phosphate dextrose as anticoagulantDouble centrifugationPlatelet concentrateActivation with CaCl2White blood cells (WBC) unreportedPlatelets 10–17×6 mL of PRP into the ruptured sitethrough a cannula and 4 mL of PRPtransdermally in the ruptured site.No beneficial effect of platelet concentrate addition in termsof the biomechanical properties of the tendon assessed byelasticity modulus. Detrimental effect of PRP compared withcontrol on Achilles tendon total rupture scores at 12 months.Alsousou et al. [9]Conservative treatmentImmunohistochemical studyPRP n = 10Unreported PRP system Locally applied PRP.PRP promotes better Collagen I deposition, decreasedcellularity, less vascularity, and higher glycosaminoglycans(GAGs) content compared with the control.Keene et al. [12]Randomized placebo-controlled trialPRP 113 n = 10Control n = 116Conservative treatmentLeukocyte-rich (LR) PRPNo activationNot ultrasound-guided (US)-guidedWBC 2.2×ErythrocytesPlatelets 4.1×Local anesthetic injection, then singlepercutaneous non-US-guided injectionof 4 mL PRP into the center of thetendon gapNo functional or clinical benefit in terms of muscle tendonmaximum work, limb symmetry index, heel rise endurancetest, pain, and adverse effects of PRP injection compared withthe placebo.De Carli et al. [11]Case seriesPRP and surgery n = 15Control, surgery only n = 15Leukocyte-poor (LP) PRPLiquid PRP, no activationGel PRP, activation with thrombin andCa-gluconatePlatelets 2–3×Addition of 2 mL of liquid PRP nearthe sutured tendon2 mL of gelatinized PRP sutured toparatenon.A second injection of 4 mL of PRP 14days post-operativelyThe addition of PRP to the surgery did not offer superiorclinical and functional outcomes in terms of Visual AnalogueScale (VAS) and isokinetic ankle plantar and dorsal flexorrange of motion compared with the control at 6 and24 months.Alviti et al. [10]Retrospective comparative studyPlatelet-rich fibrin (PRF) n = 11No PRF n = 9Healthy n = 8Surgical repairLR-PRPActivation with batroxobin and Ca-gluconateto generate a membraneApplication of fibrin glue over thesutured siteAlmost complete restoration of the biomechanics of the gait at6 months independently of the use of PRF or not. The PRFgroup showed significant improvement in efficacy of motionInt. J. Mol. Sci. 2021, 22, 824 9 of 17Table 1. Cont.Study Features of the Study PRP Characteristics Modality of Application OutcomeZou et al. [13]Prospective randomized trialPRP n = 16Control n = 20Surgical repairLR-PRPWBC 4×Platelets 6×Injection of PRP into the paratenonsheath and the surroundinglacerated tissuePRP group showed significant short and midtermimprovement in the ankle range of motion, pain, stiffness,and subjective scores (Leppilahti).At 2 years of follow-up, there were no differences between thePRP and control group for these parameters.Arriaza at et al. [8]Case seriesn = 8Surgical reconstructionCitrate as anticoagulantActivation with CaCl2Leukocyte-and erythrocyte-freePlatelets 2–3×PRGF injections into the quadricepsautograft as well as into thetendon stumpsSuccessful repair of neglected chronic Achilles tears withsignificant improvement in AOFAS score and Boydenfunctional score after 2 years of follow-up.Kaniki et al. [15]Retrospective comparative studyPRP n = 73Control n = 72Conservative treatmentLP-PRPNo activationLidocaine as anestheticNot US-guidedPlatelets 2–3×One injection of 3–4 mL of PRP into thedeep gap that was repeated 2 weeksafterwards with the same protocolNo measurable benefit of the addition of PRP to theconservative treatment in terms of strength or range ofmotion of the ankle.Boesen et al. [57]Randomized double-blindedprospective studyPRP = 19Placebo = 19Conservative treatmentLP-PRPNo activationUS-guidedPlatelets 2–3×(2.5× in one sample)One injection of PRP (4 mL) into therupture gap that was repeated every 2weeks to complete a total offour injectionsNo differences between placebo and PRP groups in term ofclinical benefits assessed by ATRS score or functionaloutcomes at any point of follow-up (2, 3, 4.5, 6, 9,and 12 months)Int. J. Mol. Sci. 2021, 22, 824 10 of 17Furthermore, these methods eliminate, reduce, or concentrate white blood cells anderythrocytes in different proportions. These two factors will strongly impinge on the bio-logical composition and therapeutic effectiveness of PRP from system to system [18,34,58].In a randomized single-blinded study conducted on 30 patients who underwent thesurgical repair of Achilles tendon rupture assisted by 10 mL of PRP injected into the rupturesite, Schepull et al. [14] did not observe any biomechanical benefit assessed by elasticitymodulus in Achilles tendon healing following rupture. However, Schepull et al. applieda platelet concentrate whose platelet concentration was about 17 times higher than thepatient’s peripheral blood only into the rupture site [14]. The presence of plasma withinPRP plays a critical role, since it conveys plasma GFs (HGF, IGF-1, FXII, and complementproteins, among others) and fibrin(ogen), whose absence renders the PRP procedure abolus delivery system of only some growth factors. This may well prevent the penetrationof GFs into tissues, as well as their spatial localization and delivery to the vicinity of cells;thus, exposing GFs to rapid proteolysis (Figure 2) [17,20,21,27].Recently, Alviti et al. [10] conducted a retrospective trial of patients with acute Achillestendon rupture who were surgically treated with or without LR-PRP matrices applied overthe suture site, and reported an almost complete restoration of the biomechanics of thegait at 6 months in both groups. However, they found that the group of patients treatedwith PRP augmentation resulted in significant functional improvements in terms of anklemotion efficiency.On the other hand, Keene et al. [12] conducted a multi-center randomized placebo-controlled trial that involved 113 patients with acute Achilles tendon rupture who weretreated with a single percutaneous injection of 4 mL of LR-PRP into the center of the tendongap following a previous injection of 1–2 mL local anesthetic into the skin area, avoidinganesthetics into the tendon itself (Figure 3B). The authors stated that the encouragingfindings in laboratory studies with PRP did not translate into a detectable patient benefitin tendon injury healing, despite the laboratory studies not recommending the use ofleukocyte PRP for the healing of injured tendons [12,34]. These and other results (Table 1)contrast with those obtained by Sanchez et al. [3] (the surgical treatment proposal in Figure3D–F) and Arriaza et al. [8], which ultimately fueled the lingering controversy surroundingwhether the inclusion of leukocytes (and erythrocytes) as key ingredients is required toachieve perfect clinical and structural outcomes in tendon repair and application pro-tocols. In this respect, the majority of experimental research suggests that white bloodcells (WBCs) exert catabolic and pro-inflammatory effects on tenocytes [28,34–36,59,60].However, the clinical outcomes of PRP injections in tendinopathies are more heteroge-neous, with some trials showing beneficial effects of LR-PRP injections compared withsaline, corticoid, or control treatments [48,49,51,52,61], whereas other studies reportingno beneficial effects of LR-PRP or whole blood [6,12,38,50,53,54,62–65]. These conflict-ing results might be partially explained by the heterogeneity of tendinopathies; the an-ticoagulation, activation, administration, and rehabilitation methods; the type of ten-don (Achilles, patella, supraspinatus, extensor carpi radialis brevis, and gluteus mediusand minimus tendons); the number of injections; and patient age [66]. Moreover, re-cent data on tendon-derived stromal fibroblasts and macrophages from patients withAchilles tendinopathy, Achilles rupture, and diseased human supraspinatus tendonshave suggested that these cells exhibit complex inflammation signatures involving theNF-κB pathway [5,43], which adds another layer of complexity to the pervasive yet in-complete degenerative paradigm of tendinopathies and tendon ruptures. Tendinopathicfibroblasts mount stronger inflammatory responses in vitro than those of healthy ham-string tendon tenocytes when exposed to IL-1β and IFNγ [5,43]; a fact associated withaltered responsiveness of NF-κB [5,67]. Conceptualized as “stromal fibroblast memory”by Dakin [5,67], this new paradigm might partially account for the lack of improvementin pain and other clinical and functional outcomes of LR-PRP on ruptured and tendino-pathic Achilles tendon, rotator cuff tendinopathies and tears, or even knee osteoarthritis,compared with placebo or saline treatments. This is likely to be partially derived fromInt. J. Mol. Sci. 2021, 22, 824 11 of 17the pro-inflammatory and catabolic-induced effects of leukocytes on inflamed stromalcells [6,12,43,50,54,63–65,68]. Accordingly, injected leukocytes may induce the release ofpro-inflammatory cytokines from primed stromal fibroblasts, which together with the detri-mental effects of erythrocyte-derived heme-iron through pro-inflammatory macrophagepolarization [44,58,68,69], may operate as non-resolving inflammation and profibroticagents, respectively [5,7,67,68], even exacerbating the inflammation-driven tendinopa-thy [64,65]. In support of this, studies on tendinopathic fibroblasts, osteoarthritis syn-oviocytes, and tendon stem cells cultured in leukocyte-containing PRP supernatant havebeen reported to release significantly higher levels of several pro-inflammatory cytokinescompared with leukocyte-depleted PRP [34–36], similar to PRP with leukocytes that simu-late the inflammatory conditions with lipopolysaccharides (LPS) and whose supernatantreleases significantly higher amounts of pro-inflammatory cytokines compared with thesupernatant of LP-PRP [59]. Finally, platelets are an important source of Lipoxin A4 (LXA4),an endogenous arachidonic acid-derived pro-resolving mediator that has been reported tocounter-regulate inflammatory processes in cells from patients with Achilles ruptures andAchilles tendinopathies [67].3.2. PRP Application ModalitiesAnother important factor in the therapeutic application outcomes of PRP relates tothe protocols utilized for its administration [17]. In a study by Keene et al. [12], the onlypercutaneous injection of non-activated PRP was infiltrated into the center of the Achillestendon gap. Similarly, Schepull et al. [14] only applied a platelet concentrate into the rupturesite following suturing. Alviti et al. [10] applied a platelet-rich fibrin (PRF) membrane butdid not infiltrate the tendon stumps, yet significant functional improvements resulted interms of the efficiency of ankle motion, contrary to Zou et al. [13], who injected into thetendon stumps but did not place a membrane, yet found biomechanical improvement overthe short and midterm compared with a control group, but not at 2 years of follow-up(Table 1). On the other hand, Arriaza et al. [8] treated eight patients with chronic Achillestears using a quadriceps tendon autograft, which was infiltrated with plasma rich in growthfactors (PRGF), as well as the Achilles tendon stumps, and reported excellent clinical andfunctional scores.Tendon rupture sites present a gap that is usually occupied by a hematoma andnecrotic tendon (Figure 3A) tissue that, in Achilles tendon ruptures treated surgically,are evacuated and debrided, respectively [42]. The ruptured areas are a source of inflam-matory mediators which stem primarily from blood-derived neutrophils and monocytes,tissue-resident macrophages, erythrocyte-derived heme iron, and dying tenocytes [68].In this context, PRP injected into the ruptured gap might exert anti-inflammatory, im-munomodulatory, anti-apoptotic, and anti-fibrotic effects, provided that the PRP compo-sition is leukocyte- and erythrocyte-free [3,34]. However, we suggest that to promote thefunctional and structural healing process of a ruptured tendon it is not enough to simplyinfiltrate PRP into the tendon gap. Further to the immunocompetent cells that reside in ahealthy and dysregulated tissues next to the damaged region [43], another important targetfor the GFs and cytokines of PRP are the healthy tendon-residing stem cells and their niches,at both the healthy proximal and distal stumps of the ruptured tendon [3,70]. These shouldalso be injected to stimulate tendon regrowth toward partially bridging the tendon gap(Figure 3C–E) [3]. Even in the best-case scenario, the function of the tendon–muscle unitwould be biomechanically compromised due to the elongation generated by the newlyformed tissue that bridges the tendon gap. Only by hypothesizing that tendon repair wouldbe specifically driven through the adaptive cellular reprogramming of adult differentiatedcells like tenocytes that survive within the hypoxic and necrotic tissue-injured microen-vironment would the tendon heal through this single injection approach and thereforeachieve the therapeutic purpose. There are several examples of this cell plasticity in tissuerepair and regeneration including fibroblast/myofibroblast differentiation, Myelin/RemakSchwann cells repairing (Bungner) Schwann cell trans-differentiation, and macrophageInt. J. Mol. Sci. 2021, 22, 824 12 of 17(M1, M2, M3, M4) and neutrophil polarization [71,72], to which PRP might contribute aswell [45,73–75].3.3. PRP Activation and pHWhereas ex vivo PRP activation with CaCl2 gives rise to a gradual liquid-to-gel dy-namic scaffold and a functionalized fibrin matrix, which circumvents the short half-lifeand the rapid GF proteolytic degradation [17,19], the direct injection of non-activatedPRP [11,12] conveys platelets that might interact with the injured tissue microenviron-ment. Whereas some platelets will be activated by tissue collagen–von Willebrand factorcomplexes, thrombin, and platelet-derived thromboxane A2 within the injured tissue [76]and release their cargo in a bolus manner, other platelets might adhere to monocytes and,through the nuclear translocation of NF-κB, induce the expression of NF-κB-dependentinflammatory genes on monocytes. In doing so, monocytes generate pro-inflammatorycytokines [77]. Furthermore, when directly injected non-activated PRP, platelets might acti-vate the complement system and promote the formation of platelet–leukocyte complexesand neutrophil extracellular traps (NETs) in situ. This may exacerbate the already in-flamed microenvironment, which may be amplified by the leukocytes of LR-PRP, as statedabove [68,77]. On the other hand, there are doubts as to whether the in vitro determinationof growth factors following the freezing of platelets and lysing them with Triton-X-100 [12]might correspond to growth factors released in vivo following contact with tendon collagen.Perhaps an in vitro activation with collagen would be more representative, since plateletsrespond differently to distinct types of stimulus. The additional activation of PRP withthrombin appears to be unnecessary, as CaCl2 adds calcium (Factor IV of the coagulationcascade), which restores extracellular matrix (ECM) calcium homeostasis and generatesa low yet efficient amount of autologous thrombin [76], thereby yielding a gradual anddynamic liquid-to gel scaffold injectable within a roughly 1–5 min window, during whichPRP is macroscopically manageable as a liquid, or a fibrin membrane 20 min following ac-tivation [3,17,19,23,42]. However, whereas low concentrations of thrombin exhibit growthfactor-like fibroblast and endothelial cell proliferation migration, antiapoptotic, and inflam-matory modulation activities, high doses of thrombin would operate as an inflammatorymediator that recruits monocytes, activates the NF-κB of endothelial cells, and triggers therelease of cytokines from mast cells [24,76]. Moreover, exogenous activation with commer-cially available thrombin (bovine) might be associated with adverse effects, which includeimmune reactions, thrombosis, and hemorrhages [78].Another area of concern relates to the pH of PRP, where PRP preparation devices andstudies should provide its precise characterization, which should also include the pH of theproduct that is ready to be injected, among many other parameters that convey its biologicalproperties [18,35]. In some studies, based on the acidic properties of acid citrate dextrose(ACD), which is used as anticoagulant, a basic buffer solution of 8.4% sodium bicarbonatewas added to adjust an unknown PRP pH to physiologic pH prior to injection to addressAchilles or tennis elbow tendinopathy [38,53,54,79]. As examples, the excellently designedand carefully conducted trials by Krogh et al. [53,54], who, through the use of an ultrasound-guided single percutaneous injection of LR-PRP into the elbow lateral common tendonand Achilles tendon, respectively, did not observe any clinical or functional improvementcompared with a saline or glucocorticoid group. It is worthy of note that the acidityof plasma is contingent on the quantity of citrate used [79]. Some PRP devices may ormay not use ACD as an anticoagulant (PRP pH values of 7.0 and 8.0 respectively) and,due to its acidic pH (ACD presents a pH=4.98 [35]), device manufacturers recommendthe use of 8.4% sodium bicarbonate in the former procedure (Biomet GPS III, BiometBiologics). Similarly, the pH values of other commercial PRP kits using ACD ranged from6.59 (SmartPrep2, Terumo Harvest) to 7.05 (GPS III, Biomet Biologics) in the measuresreported by Fitzpatrick et al. [80]. Accordingly, in a technical analysis of PRP applied totreat tendinopathies, Kaux et al. [81] reported that in the majority of studies that usedACD as an anticoagulant, researchers added a buffer solution. However, other devices thatInt. J. Mol. Sci. 2021, 22, 824 13 of 17also use citrate (trisodium citrate) [79] present a pH of 7.64 ± 0.09 prior to activation and7.53± 0.09 once it has been activated with 10% CaCl2 [82]. These pH values are far differentfrom the acidic pH values reported by some studies and are attributed to CaCl2 (pH of6.3) [18,78], which makes the addition of a buffer solution unnecessary in this case [82].Importantly, the associated administration of local anesthetics (bupivacaine and lidocaine)and corticoids (methylprednisolone) with PRP should be avoided, since it has been reportedthat these drugs decrease the viability and proliferation of tenocytes [38,83,84].4. Future PerspectivesSelecting the right biological scaffold and applying it correctly to restitutio ad integrumof ruptured Achilles tendons remains a daunting and complex task. Although PRP hasmany characteristics that make it an attractive treatment, its application is still nascent.The scientific community continues to learn and garner valuable insights to enhance thepotential of PRP treatment via intellectual, technological, and research efforts into some ofthe biological and practical bottlenecks. Prior use and research of PRP has failed to fullyaddress issues to optimize structural and functional PRP-mediated tendon repair outcomes;therefore, the clinical use of and research into PRP in the treatment of Achilles tendon tearshas now been limited to its use as adjunctive treatment with surgery. The advances thatemerge from synergies between natural and synthetic biology will lead to the generationof optimal biological scaffolds and guide their best possible application in the treatment ofAchilles tendons in conjunction with functional rehabilitation.Author Contributions: Conceptualization: S.P., E.A., M.S., J.T., and R.C.; methodology: S.P., E.A.,R.P., F.B., and G.S.; writing—original draft: S.P. and E.A.; writing—review and editing: S.P., E.A, M.S.,J.T., R.P., F.B., G.A.M., C.J.R., S.S., R.E., R.C., V.V., N.F., J.A., G.S., and R.S. All authors have read andagreed to the published version of the manuscript.Funding: This research received no external funding.Institutional Review Board Statement: Not applicable.Informed Consent Statement: Not applicable.Data Availability Statement: Not applicable.Conflicts of Interest: The authors declare that E.A. is the Scientific Director of and S.P. and R.P.are scientists at BTI Biotechnology Institute, a biomedical company that investigates in the fields ofregenerative medicine and PRGF-Endoret technology. The rest of the authors state that that theyhave no conflicts of interest that are relevant to the content of this article.References1. Park, S.H.; Lee, H.S.; Young, K.W.; Seo, S.G. Treatment of Acute Achilles Tendon Rupture. Clin. Orthop. Surg. 2020, 12, 1–8.[CrossRef] [PubMed]2. Sanchez, M.; Anitua, E.; Orive, G.; Mujika, I.; Andia, I. Platelet-rich therapies in the treatment of orthopaedic sport injuries.Sports Med. 2009, 39, 345–354. [CrossRef] [PubMed]3. Sanchez, M.; Anitua, E.; Azofra, J.; Andia, I.; Padilla, S.; Mujika, I. Comparison of surgically repaired Achilles tendon tears usingplatelet-rich fibrin matrices. Am. J. Sports Med. 2007, 35, 245–251. [CrossRef] [PubMed]4. Millar, N.L.; Murrell, G.A.C.; McInnes, I.B. Inflammatory mechanisms in tendinopathy—Towards translation. Nat. Rev. Rheumatol.2017, 13, 110–122. [CrossRef] [PubMed]5. Dakin, S.G.; Buckley, C.D.; Al-Mossawi, M.H.; Hedley, R.; Martinez, F.O.; Wheway, K.; Watkins, B.; Carr, A.J. Persistent stromalfibroblast activation is present in chronic tendinopathy. Arthritis Res. Ther. 2017, 19, 16. [CrossRef]6. Carr, A.J.; Murphy, R.; Dakin, S.G.; Rombach, I.; Wheway, K.; Watkins, B.; Franklin, S.L. Platelet-Rich Plasma Injection withArthroscopic Acromioplasty for Chronic Rotator Cuff Tendinopathy: A Randomized Controlled Trial. Am. J. Sports Med. 2015, 43,2891–2897. [CrossRef]7. Rees, J.D.; Stride, M.; Scott, A. Tendons—Time to revisit inflammation. Br. J. Sports Med. 2014, 48, 1553–1557. [CrossRef]8. Arriaza, R.; Arriaza, A.; Lopez-Vidriero, E.; Gayoso, R.; Agrasar, C.; Saavedra-Garcia, M.A. Quadriceps tendon autograft and plateletrich plasma injection to treat chronic Achilles tears-a minimum two-year follow-up. Ann. Transl. Med. 2019, 7, 746. [CrossRef]9. Alsousou, J.; Thompson, M.; Harrison, P.; Willett, K.; Franklin, S. Effect of platelet-rich plasma on healing tissues in acute rupturedAchilles tendon: A human immunohistochemistry study. Lancet 2015, 385 (Suppl. 1), S19. [CrossRef]Int. J. Mol. Sci. 2021, 22, 824 14 of 1710. Alviti, F.; Gurzi, M.; Santilli, V.; Paoloni, M.; Padua, R.; Bernetti, A.; Bernardi, M.; Mangone, M. Achilles Tendon Open SurgicalTreatment with Platelet-Rich Fibrin Matrix Augmentation: Biomechanical Evaluation. J. Foot Ankle Surg. 2017, 56, 581–585.[CrossRef]11. De Carli, A.; Lanzetti, R.M.; Ciompi, A.; Lupariello, D.; Vadala, A.; Argento, G.; Ferretti, A.; Vulpiani, M.C.; Vetrano, M.Can platelet-rich plasma have a role in Achilles tendon surgical repair? Knee Surg. Sports Traumatol. Arthrosc. 2016, 24, 2231–2237.[CrossRef] [PubMed]12. Keene, D.J.; Alsousou, J.; Harrison, P.; Hulley, P.; Wagland, S.; Parsons, S.R.; Thompson, J.Y.; O’Connor, H.M.; Schlussel, M.M.;Dutton, S.J.; et al. Platelet rich plasma injection for acute Achilles tendon rupture: PATH-2 randomised, placebo controlled,superiority trial. BMJ 2019, 367, l6132. [CrossRef] [PubMed]13. Zou, J.; Mo, X.; Shi, Z.; Li, T.; Xue, J.; Mei, G.; Li, X. A Prospective Study of Platelet-Rich Plasma as Biological Augmentation forAcute Achilles Tendon Rupture Repair. BioMed Res. Int. 2016, 2016, 9364170. [CrossRef] [PubMed]14. Schepull, T.; Kvist, J.; Norrman, H.; Trinks, M.; Berlin, G.; Aspenberg, P. Autologous platelets have no effect on the healing ofhuman achilles tendon ruptures: A randomized single-blind study. Am. J. Sports Med. 2011, 39, 38–47. [CrossRef] [PubMed]15. Kaniki, N.; Willits, K.; Mohtadi, N.G.; Fung, V.; Bryant, D. A retrospective comparative study with historical control to determinethe effectiveness of platelet-rich plasma as part of nonoperative treatment of acute achilles tendon rupture. Arthroscopy 2014, 30,1139–1145. [CrossRef]16. Nourissat, G.; Ornetti, P.; Berenbaum, F.; Sellam, J.; Richette, P.; Chevalier, X. Does platelet-rich plasma deserve a role in thetreatment of tendinopathy? Jt. Bone Spine 2015, 82, 230–234. [CrossRef]17. Anitua, E.; Nurden, P.; Prado, R.; Nurden, A.T.; Padilla, S. Autologous fibrin scaffolds: When platelet- and plasma-derivedbiomolecules meet fibrin. Biomaterials 2019, 192, 440–460. [CrossRef]18. DeLong, J.M.; Russell, R.P.; Mazzocca, A.D. Platelet-rich plasma: The PAW classification system. Arthroscopy 2012, 28, 998–1009.[CrossRef]19. Anitua, E. Plasma rich in growth factors: Preliminary results of use in the preparation of future sites for implants. Int. J. OralMaxillofac. Implants 1999, 14, 529–535.20. Sarrazin, S.; Lamanna, W.C.; Esko, J.D. Heparan sulfate proteoglycans. Cold Spring Harb. Perspect. Biol. 2011, 3, a004952. [CrossRef]21. Martino, M.M.; Briquez, P.S.; Guc, E.; Tortelli, F.; Kilarski, W.W.; Metzger, S.; Rice, J.J.; Kuhn, G.A.; Muller, R.; Swartz, M.A.;et al. Growth factors engineered for super-affinity to the extracellular matrix enhance tissue healing. Science 2014, 343, 885–888.[CrossRef] [PubMed]22. Mitchell, A.C.; Briquez, P.S.; Hubbell, J.A.; Cochran, J.R. Engineering growth factors for regenerative medicine applications.Acta Biomater. 2016, 30, 1–12. [CrossRef] [PubMed]23. Anitua, E.; Prado, R.; Azkargorta, M.; Rodriguez-Suarez, E.; Iloro, I.; Casado-Vela, J.; Elortza, F.; Orive, G. High-throughputproteomic characterization of plasma rich in growth factors (PRGF-Endoret)-derived fibrin clot interactome. J. Tissue Eng.Regen. Med. 2015, 9, E1–E12. [CrossRef] [PubMed]24. Strukova, S. Blood coagulation-dependent inflammation. Coagulation-dependent inflammation and inflammation-dependentthrombosis. Front. Biosci. 2006, 11, 59–80. [CrossRef]25. Briquez, P.S.; Hubbell, J.A.; Martino, M.M. Extracellular Matrix-Inspired Growth Factor Delivery Systems for Skin WoundHealing. Adv. Wound Care 2015, 4, 479–489. [CrossRef]26. Neuss, S.; Schneider, R.K.; Tietze, L.; Knüchel, R.; Jahnen-Dechent, W. Secretion of fibrinolytic enzymes facilitates humanmesenchymal stem cell invasion into fibrin clots. Cells Tissues Organs 2010, 191, 36–46. [CrossRef]27. Sacchi, V.; Mittermayr, R.; Hartinger, J.; Martino, M.M.; Lorentz, K.M.; Wolbank, S.; Hofmann, A.; Largo, R.A.; Marschall, J.S.;Groppa, E.; et al. Long-lasting fibrin matrices ensure stable and functional angiogenesis by highly tunable, sustained delivery ofrecombinant VEGF164. Proc. Natl. Acad. Sci. USA 2014, 111, 6952–6957. [CrossRef]28. Anitua, E.; Zalduendo, M.M.; Prado, R.; Alkhraisat, M.H.; Orive, G. Morphogen and proinflammatory cytokine release kineticsfrom PRGF-Endoret fibrin scaffolds: Evaluation of the effect of leukocyte inclusion. J. Biomed. Mater. Res. A 2015, 103, 1011–1020.[CrossRef]29. Janmey, P.A.; Miller, R.T. Mechanisms of mechanical signaling in development and disease. J. Cell Sci. 2011, 124, 9–18. [CrossRef]30. Anitua, E.; Sanchez, M.; Nurden, A.T.; Zalduendo, M.; de la Fuente, M.; Orive, G.; Azofra, J.; Andia, I. Autologous fibrin matrices:A potential source of biological mediators that modulate tendon cell activities. J. Biomed. Mater. Res. A 2006, 77, 285–293. [CrossRef]31. Sanchez, M.; Anitua, E.; Azofra, J.; Prado, R.; Muruzabal, F.; Andia, I. Ligamentization of tendon grafts treated with an endogenouspreparation rich in growth factors: Gross morphology and histology. Arthroscopy 2010, 26, 470–480. [CrossRef] [PubMed]32. Jo, C.H.; Kim, J.E.; Yoon, K.S.; Shin, S. Platelet-rich plasma stimulates cell proliferation and enhances matrix gene expressionand synthesis in tenocytes from human rotator cuff tendons with degenerative tears. Am. J. Sports Med. 2012, 40, 1035–1045.[CrossRef] [PubMed]33. Chen, L.; Liu, J.P.; Tang, K.L.; Wang, Q.; Wang, G.D.; Cai, X.H.; Liu, X.M. Tendon derived stem cells promote platelet-rich plasmahealing in collagenase-induced rat achilles tendinopathy. Cell. Physiol. Biochem. 2014, 34, 2153–2168. [CrossRef] [PubMed]34. Zhou, Y.; Zhang, J.; Wu, H.; Hogan, M.V.; Wang, J.H. The differential effects of leukocyte-containing and pure platelet-rich plasma(PRP) on tendon stem/progenitor cells—Implications of PRP application for the clinical treatment of tendon injuries. Stem Cell.Res. Ther. 2015, 6, 173. [CrossRef] [PubMed]Int. J. Mol. Sci. 2021, 22, 824 15 of 1735. Cross, J.A.; Cole, B.J.; Spatny, K.P.; Sundman, E.; Romeo, A.A.; Nicholson, G.P.; Wagner, B.; Fortier, L.A. Leukocyte-ReducedPlatelet-Rich Plasma Normalizes Matrix Metabolism in Torn Human Rotator Cuff Tendons. Am. J. Sports Med. 2015, 43, 2898–2906.[CrossRef] [PubMed]36. Yan, R.; Gu, Y.; Ran, J.; Hu, Y.; Zheng, Z.; Zeng, M.; Heng, B.C.; Chen, X.; Yin, Z.; Chen, W.; et al. Intratendon Delivery ofLeukocyte-Poor Platelet-Rich Plasma Improves Healing Compared With Leukocyte-Rich Platelet-Rich Plasma in a Rabbit AchillesTendinopathy Model. Am. J. Sports Med. 2017, 45, 1909–1920. [CrossRef]37. De Almeida, A.M.; Demange, M.K.; Sobrado, M.F.; Rodrigues, M.B.; Pedrinelli, A.; Hernandez, A.J. Patellar tendon healing withplatelet-rich plasma: A prospective randomized controlled trial. Am. J. Sports Med. 2012, 40, 1282–1288. [CrossRef]38. Gosens, T.; Den Oudsten, B.L.; Fievez, E.; van’t Spijker, P.; Fievez, A. Pain and activity levels before and after platelet-rich plasmainjection treatment of patellar tendinopathy: A prospective cohort study and the influence of previous treatments. Int. Orthop.2012, 36, 1941–1946. [CrossRef]39. Aspenberg, P.; Virchenko, O. Platelet concentrate injection improves Achilles tendon repair in rats. Acta Orthop. Scand. 2004, 75,93–99. [CrossRef]40. Lopez-Najera, D.; Rubio-Zaragoza, M.; Sopena-Juncosa, J.J.; Alentorn-Geli, E.; Cugat-Bertomeu, R.; Fernandez-Sarmiento, J.A.;Dominguez-Perez, J.M.; Garcia-Balletbo, M.; Primo-Capella, V.J.; Carrillo-Poveda, J.M. Effects of plasma rich in growth factors (PRGF)on biomechanical properties of Achilles tendon repair. Knee Surg. Sports Traumatol. Arthrosc. 2016, 24, 3997–4004. [CrossRef]41. Borselli, C.; Storrie, H.; Benesch-Lee, F.; Shvartsman, D.; Cezar, C.; Lichtman, J.W.; Vandenburgh, H.H.; Mooney, D.J. Functionalmuscle regeneration with combined delivery of angiogenesis and myogenesis factors. Proc. Natl. Acad. Sci. USA 2010, 107,3287–3292. [CrossRef] [PubMed]42. Sánchez, M.; Delgado, D.; Garate, A.; Sánchez, P.; Oraa, J.; Bilbao, A.M.; Guadilla, J.; Aizpurua, B.; Fiz, N.; Azofra, J.; et al.PRP Injections in Orthopaedic Surgery: Why, When and How to Use PRP Dynamic Liquid Scaffold Injections in OrthopaedicSurgery. In Plasma Medicine—Concepts and Clinical Applications; Tutar, Y., Tutar, L., Eds.; IntechOpen: London, UK, 2018.43. Dakin, S.G.; Newton, J.; Martinez, F.O.; Hedley, R.; Gwilym, S.; Jones, N.; Reid, H.A.B.; Wood, S.; Wells, G.; Appleton, L.; et al.Chronic inflammation is a feature of Achilles tendinopathy and rupture. Br. J. Sports Med. 2018, 52, 359–367. [CrossRef] [PubMed]44. Dakin, S.G.; Coles, M.; Sherlock, J.P.; Powrie, F.; Carr, A.J.; Buckley, C.D. Pathogenic stromal cells as therapeutic targets in jointinflammation. Nat. Rev. Rheumatol. 2018, 14, 714–726. [CrossRef] [PubMed]45. Nishio, H.; Saita, Y.; Kobayashi, Y.; Takaku, T.; Fukusato, S.; Uchino, S.; Wakayama, T.; Ikeda, H.; Kaneko, K. Platelet-rich plasmapromotes recruitment of macrophages in the process of tendon healing. Regen. Ther. 2020, 14, 262–270. [CrossRef] [PubMed]46. Chernysh, I.N.; Weisel, J.W. Dynamic imaging of fibrin network formation correlated with other measures of polymerization.Blood 2008, 111, 4854–4861. [CrossRef] [PubMed]47. Neph, A.; Schroeder, A.; Enseki, K.R.; Everts, P.A.; Wang, J.H.; Onishi, K. Role of Mechanical Loading for Platelet-Rich Plasma-Treated Achilles Tendinopathy. Curr. Sports Med. Rep. 2020, 19, 209–216. [CrossRef] [PubMed]48. Fitzpatrick, J.; Bulsara, M.K.; O’Donnell, J.; Zheng, M.H. Leucocyte-Rich Platelet-Rich Plasma Treatment of Gluteus Mediusand Minimus Tendinopathy: A Double-Blind Randomized Controlled Trial with 2-Year Follow-up. Am. J. Sports Med. 2019, 47,1130–1137. [CrossRef]49. Fitzpatrick, J.; Bulsara, M.K.; O’Donnell, J.; McCrory, P.R.; Zheng, M.H. The Effectiveness of Platelet-Rich Plasma Injections inGluteal Tendinopathy: A Randomized, Double-Blind Controlled Trial Comparing a Single Platelet-Rich Plasma Injection With aSingle Corticosteroid Injection. Am. J. Sports Med. 2018, 46, 933–939. [CrossRef]50. De Vos, R.J.; Weir, A.; van Schie, H.T.; Bierma-Zeinstra, S.M.; Verhaar, J.A.; Weinans, H.; Tol, J.L. Platelet-rich plasma injection forchronic Achilles tendinopathy: A randomized controlled trial. JAMA 2010, 303, 144–149. [CrossRef]51. Dragoo, J.L.; Wasterlain, A.S.; Braun, H.J.; Nead, K.T. Platelet-rich plasma as a treatment for patellar tendinopathy: A double-blind,randomized controlled trial. Am. J. Sports Med. 2014, 42, 610–618. [CrossRef]52. Mishra, A.K.; Skrepnik, N.V.; Edwards, S.G.; Jones, G.L.; Sampson, S.; Vermillion, D.A.; Ramsey, M.L.; Karli, D.C.; Rettig, A.C.Efficacy of platelet-rich plasma for chronic tennis elbow: A double-blind, prospective, multicenter, randomized controlled trial of230 patients. Am. J. Sports Med. 2014, 42, 463–471. [CrossRef] [PubMed]53. Krogh, T.P.; Fredberg, U.; Stengaard-Pedersen, K.; Christensen, R.; Jensen, P.; Ellingsen, T. Treatment of lateral epicondylitis withplatelet-rich plasma, glucocorticoid, or saline: A randomized, double-blind, placebo-controlled trial. Am. J. Sports Med. 2013, 41,625–635. [CrossRef] [PubMed]54. Krogh, T.P.; Ellingsen, T.; Christensen, R.; Jensen, P.; Fredberg, U. Ultrasound-Guided Injection Therapy of Achilles Tendinopathywith Platelet-Rich Plasma or Saline: A Randomized, Blinded, Placebo-Controlled Trial. Am. J. Sports Med. 2016, 44, 1990–1997.[CrossRef] [PubMed]55. Fitzpatrick, J.; Bulsara, M.; Zheng, M.H. The Effectiveness of Platelet-Rich Plasma in the Treatment of Tendinopathy: A Meta-analysis of Randomized Controlled Clinical Trials. Am. J. Sports Med. 2017, 45, 226–233. [CrossRef] [PubMed]56. Sánchez, M.; Anitua, E.; Cole, A.; Da Silva, A.; Azofra, J.; Andia, I. Management of post-surgical Achilles tendon complicationswith a preparation rich in growth factors: A study of two-cases. Inj. Extra 2009, 40, 11–15. [CrossRef]57. Boesen, A.P.; Boesen, M.I.; Hansen, R.; Barfod, K.W.; Lenskjold, A.; Malliaras, P.; Langberg, H. Effect of Platelet-Rich Plasma onNonsurgically Treated Acute Achilles Tendon Ruptures: A Randomized, Double-Blinded Prospective Study. Am. J. Sports Med.2020, 48, 2268–2276. [CrossRef]Int. J. Mol. Sci. 2021, 22, 824 16 of 1758. Everts, P.A.; Malanga, G.A.; Paul, R.V.; Rothenberg, J.B.; Stephens, N.; Mautner, K.R. Assessing clinical implications andperspectives of the pathophysiological effects of erythrocytes and plasma free hemoglobin in autologous biologics for use inmusculoskeletal regenerative medicine therapies. A review. Regen. Ther. 2019, 11, 56–64. [CrossRef]59. Anitua, E.; Zalduendo, M.; Troya, M.; Padilla, S.; Orive, G. Leukocyte inclusion within a platelet rich plasma-derived fibrinscaffold stimulates a more pro-inflammatory environment and alters fibrin properties. PLoS ONE 2015, 10, e0121713. [CrossRef]60. Hudgens, J.L.; Sugg, K.B.; Grekin, J.A.; Gumucio, J.P.; Bedi, A.; Mendias, C.L. Platelet-Rich Plasma Activates ProinflammatorySignaling Pathways and Induces Oxidative Stress in Tendon Fibroblasts. Am. J. Sports Med. 2016, 44, 1931–1940. [CrossRef]61. Gosens, T.; Peerbooms, J.C.; van Laar, W.; den Oudsten, B.L. Ongoing positive effect of platelet-rich plasma versus corticosteroidinjection in lateral epicondylitis: A double-blind randomized controlled trial with 2-year follow-up. Am. J. Sports Med. 2011, 39,1200–1208. [CrossRef]62. Bell, K.J.; Fulcher, M.L.; Rowlands, D.S.; Kerse, N. Impact of autologous blood injections in treatment of mid-portion Achillestendinopathy: Double blind randomised controlled trial. BMJ 2013, 346, f2310. [CrossRef]63. De Vos, R.J.; Weir, A.; Tol, J.L.; Verhaar, J.A.; Weinans, H.; van Schie, H.T. No effects of PRP on ultrasonographic tendon structureand neovascularisation in chronic midportion Achilles tendinopathy. Br. J. Sports Med. 2011, 45, 387–392. [CrossRef]64. Schwitzguebel, A.J.; Kolo, F.C.; Tirefort, J.; Kourhani, A.; Nowak, A.; Gremeaux, V.; Saffarini, M.; Ladermann, A. Efficacy ofPlatelet-Rich Plasma for the Treatment of Interstitial Supraspinatus Tears: A Double-Blinded, Randomized Controlled Trial. Am. J.Sports Med. 2019, 47, 1885–1892. [CrossRef]65. Scott, A.; LaPrade, R.F.; Harmon, K.G.; Filardo, G.; Kon, E.; Della Villa, S.; Bahr, R.; Moksnes, H.; Torgalsen, T.; Lee, J.; et al.Platelet-Rich Plasma for Patellar Tendinopathy: A Randomized Controlled Trial of Leukocyte-Rich PRP or Leukocyte-Poor PRPVersus Saline. Am. J. Sports Med. 2019, 47, 1654–1661. [CrossRef]66. Abat, F.; Alfredson, H.; Cucchiarini, M.; Madry, H.; Marmotti, A.; Mouton, C.; Oliveira, J.M.; Pereira, H.; Peretti, G.M.;Spang, C.; et al. Current trends in tendinopathy: Consensus of the ESSKA basic science committee. Part II: Treatment options.J. Exp. Orthop. 2018, 5, 38. [CrossRef]67. Dakin, S.G.; Colas, R.A.; Newton, J.; Gwilym, S.; Jones, N.; Reid, H.A.B.; Wood, S.; Appleton, L.; Wheway, K.; Watkins, B.; et al.15-Epi-LXA4 and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture. FASEB J.2019, 33, 8043–8054. [CrossRef] [PubMed]68. Scott, A.; Khan, K.M.; Roberts, C.R.; Cook, J.L.; Duronio, V. What do we mean by the term “inflammation”? A contemporarybasic science update for sports medicine. Br. J. Sports Med. 2004, 38, 372–380. [CrossRef] [PubMed]69. Soares, M.P.; Hamza, I. Macrophages and Iron Metabolism. Immunity 2016, 44, 492–504. [CrossRef] [PubMed]70. Zhang, J.; Middleton, K.K.; Fu, F.H.; Im, H.J.; Wang, J.H. HGF mediates the anti-inflammatory effects of PRP on injured tendons.PLoS ONE 2013, 8, e67303. [CrossRef] [PubMed]71. Mosteiro, L.; Pantoja, C.; Alcazar, N.; Marion, R.M.; Chondronasiou, D.; Rovira, M.; Fernandez-Marcos, P.J.; Munoz-Martin, M.;Blanco-Aparicio, C.; Pastor, J.; et al. Tissue damage and senescence provide critical signals for cellular reprogramming in vivo.Science 2016, 354, aaf4445. [CrossRef]72. Jessen, K.R.; Mirsky, R. The repair Schwann cell and its function in regenerating nerves. J. Physiol. 2016, 594, 3521–3531. [CrossRef][PubMed]73. Anitua, E.; Sanchez, M.; Merayo-Lloves, J.; De la Fuente, M.; Muruzabal, F.; Orive, G. Plasma rich in growth factors (PRGF-Endoret) stimulates proliferation and migration of primary keratocytes and conjunctival fibroblasts and inhibits and revertsTGF-beta1-Induced myodifferentiation. Investig. Ophthalmol. Vis. Sci. 2011, 52, 6066–6073. [CrossRef] [PubMed]74. Renn, T.Y.; Kao, Y.H.; Wang, C.C.; Burnouf, T. Anti-inflammatory effects of platelet biomaterials in a macrophage cellular model.Vox Sang. 2015, 109, 138–147. [CrossRef] [PubMed]75. Vasina, E.M.; Cauwenberghs, S.; Feijge, M.A.; Heemskerk, J.W.; Weber, C.; Koenen, R.R. Microparticles from apoptotic plateletspromote resident macrophage differentiation. Cell Death Dis. 2011, 2, e211. [CrossRef] [PubMed]76. Estevez, B.; Du, X. New Concepts and Mechanisms of Platelet Activation Signaling. Physiology (Bethesda) 2017, 32, 162–177.[CrossRef]77. Vieira-de-Abreu, A.; Campbell, R.A.; Weyrich, A.S.; Zimmerman, G.A. Platelets: Versatile effector cells in hemostasis, inflamma-tion, and the immune continuum. Semin. Immunopathol. 2012, 34, 5–30. [CrossRef]78. Lansdown, D.A.; Fortier, L.A. Platelet-Rich Plasma: Formulations, Preparations, Constituents, and Their Effects. Oper. Tech. SportsMed. 2017, 25, 7–12. [CrossRef]79. Laffan, M.; Manning, R. Chapter 16—Investigation of haemostasis. In Dacie and Lewis Practical Haematology, 10th ed.; Lewis, S.M.,Bain, B.J., Bates, I., Eds.; Churchill Livingstone: Philadelphia, PA, USA, 2006; pp. 379–440.80. Fitzpatrick, J.; Bulsara, M.K.; McCrory, P.R.; Richardson, M.D.; Zheng, M.H. Analysis of Platelet-Rich Plasma Extraction: Variationsin Platelet and Blood Components between 4 Common Commercial Kits. Orthop. J. Sports Med. 2017, 5, 2325967116675272.[CrossRef]81. Kaux, J.F.; Emonds-Alt, T. The use of platelet-rich plasma to treat chronic tendinopathies: A technical analysis. Platelets 2018, 29,213–227. [CrossRef]82. Anitua, E.; de la Fuente, M.; Alcalde, I.; Sanchez, C.; Merayo-Lloves, J.; Muruzabal, F. Development and Optimization ofFreeze-Dried Eye Drops Derived from Plasma Rich in Growth Factors Technology. Transl. Vis. Sci. Technol. 2020, 9, 35. [CrossRef]Int. J. Mol. Sci. 2021, 22, 824 17 of 1783. Beitzel, K.; McCarthy, M.B.; Cote, M.P.; Apostolakos, J.; Russell, R.P.; Bradley, J.; ElAttrache, N.S.; Romeo, A.A.; Arciero, R.A.;Mazzocca, A.D. The effect of ketorolac tromethamine, methylprednisolone, and platelet-rich plasma on human chondrocyte andtenocyte viability. Arthroscopy 2013, 29, 1164–1174. [CrossRef] [PubMed]84. Carofino, B.; Chowaniec, D.M.; McCarthy, M.B.; Bradley, J.P.; Delaronde, S.; Beitzel, K.; Cote, M.P.; Arciero, R.A.; Mazzocca, A.D.Corticosteroids and local anesthetics decrease positive effects of platelet-rich plasma: An in vitro study on human tendon cells.Arthroscopy 2012, 28, 711–719. [CrossRef] [PubMed]
Article
eng
Reviewed
Vancouver : University of British Columbia Library
Multidisciplinary Digital Publishing Institute
CC BY 4.0
Faculty
Researcher
Achilles
platelet-rich plasma
PRGF
tendon
Platelet-Rich Plasma Applications for Achilles Tendon Repair: A Bridge between Biology and Surgery
Text